Exogen Biotechnology, Inc.

Exogen Biotechnology is a Berkeley-based healthcare startup dedicated to quantifying DNA damage and assessing cellular DNA repair capacities. Over 40% of the US population will be diagnosed with cancer and doctors desperately need a way to identify at risk cancer patients and stratify cancer patients for various treatment options. Exogen Bio has developed a technology capable of identifying novel DNA prognostic markers that allows clinicians to better prevent and treat cancer.

Deepcell, Inc.

Deepcell aims to provide detailed genetic health information through ordinary blood sampling. DeepCell's mission is to eliminate the need for invasive diagnostic tests.

BioPet Laboratories

BioPet Laboratories is a biotechnology company specializing in animal genomics. BioPet offers multiple product and services: PooPrints®, the DNA Solution for Dog Waste; BioPet Life Plan™, an interactive canine health and wellness management tool with Breed and Allergy Testing; DNA Proof of Parentage, canine parentage testing certification; Travel Dog™, an elite club for dogs and their owners; and the DNA World Pet Registry®, a state of the art database to store canine genetic information. As the parent company of the PooPrints® program BioPet works with more than 3,000 multifamily properties worldwide. With more than 250,000 individual canines in their database, BioPet is becoming an industry standard for canine genetics. BioPet was the first to offer a ground breaking price point reductions and one of the fastest processing times in the canine paternity industry. Historically excelling in canine DNA offerings such as breed analysis, parentage verification, and DNA matching of fecal samples, BioPet has now optimized a cattle parentage test and DNA source verification of beef and is working to expand its offerings beyond the canine realm. *BioPet Laboratories is accredited to the ISO/IEC 17025:2005 standard*

BioVendor, LLC

Established in 2004 as a daughter company of the Czech company BioVendor – Laboratorni medicina a.s. (Est. 1992), as a supplier of immunoassays, antibodies, recombinant proteins, and endotoxin removal and detection products. BioVendor's R&D efforts are aimed at rapidly growing fields of interest within the international research and diagnostic community, such as Obesity/Metabolic syndrome/Diabetes, Cardiovascular physiology, Renal disease and injury, Bone metabolism/Os­teoporosis, Infection/Inflam­mation, Oncology/Tumor markers and more. BioVendor products are the result of long-term R&D activities, based on the capability of our research professionals to set new targets and to develop and manufacture new products, some of which being unique in the world, or being the first commercial assays, recombinant proteins or antibodies available on the market. BioVendor also distributes Hyglos GMBH endotoxin removal products and detection assays which rely on recombinant technology instead of horseshoe crab blood. These products are highly specific, have low lot-to-lot variability, and enable users to measure endotoxin in more complex samples than is allowable from other commercial assays. Oure parent company, BioVendor – Laboratorni medicina a.s., is EN ISO 13485:2000, ISO 9001:2000 and ISO 14001 certified, assuring that the development and manufacturing processes of all our products meet all quality control as well as environmental management criteria required.

Biopharm Inc